These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 35102468)

  • 1. Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future.
    Cheng Z; Du Y; Yu L; Yuan Z; Tian J
    Mol Imaging Biol; 2022 Apr; 24(2):264-279. PubMed ID: 35102468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive imaging in cancer immunotherapy: The way to precision medicine.
    Du Y; Qi Y; Jin Z; Tian J
    Cancer Lett; 2019 Dec; 466():13-22. PubMed ID: 31499119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer.
    Jalalvand M; Darbeheshti F; Rezaei N
    Immunotherapy; 2021 May; 13(7):587-603. PubMed ID: 33775102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospect of immunotherapy in neoadjuvant/adjuvant treatment for early breast cancer.
    Miyashita M; Ishida T
    Chin Clin Oncol; 2020 Jun; 9(3):28. PubMed ID: 32312056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Tumor Markers for Breast Cancer Immunotherapy.
    Fang Q; Shen G; Xie Q; Guan Y; Liu X; Ren D; Zhao F; Liu Z; Ma F; Zhao J
    Curr Mol Med; 2024; 24(5):547-564. PubMed ID: 37157196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
    Zeng Z; Yang B; Liao Z
    Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
    Qian X; Hu W; Yan J
    Front Immunol; 2022; 13():963533. PubMed ID: 36016946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer.
    Noguchi E; Shien T; Iwata H
    Jpn J Clin Oncol; 2021 Mar; 51(3):321-332. PubMed ID: 33324990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer.
    Gaynor N; Crown J; Collins DM
    Semin Cancer Biol; 2022 Feb; 79():44-57. PubMed ID: 32623044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapeutic strategies in breast cancer: A clinical update.
    Zhang JQ; Plitas G
    J Surg Oncol; 2021 Mar; 123(3):710-717. PubMed ID: 33155281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy.
    Gorbet MJ; Ranjan A
    Pharmacol Ther; 2020 Mar; 207():107456. PubMed ID: 31863820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
    Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
    Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies.
    Cilibrasi C; Papanastasopoulos P; Samuels M; Giamas G
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 status in breast cancer: Current view and perspectives.
    Vranic S; Cyprian FS; Gatalica Z; Palazzo J
    Semin Cancer Biol; 2021 Jul; 72():146-154. PubMed ID: 31883913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
    Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
    Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
    Zhang J; Dai Z; Yan C; Zhang W; Wang D; Tang D
    Clin Transl Oncol; 2021 Dec; 23(12):2415-2430. PubMed ID: 34125407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer.
    Jungles KM; Holcomb EA; Pearson AN; Jungles KR; Bishop CR; Pierce LJ; Green MD; Speers CW
    Front Oncol; 2022; 12():1022542. PubMed ID: 36387071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle.
    Masoumi E; Tahaghoghi-Hajghorbani S; Jafarzadeh L; Sanaei MJ; Pourbagheri-Sigaroodi A; Bashash D
    J Control Release; 2021 Dec; 340():168-187. PubMed ID: 34743998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy.
    Nakajima H; Nakatsura T
    Immunol Med; 2021 Mar; 44(1):10-15. PubMed ID: 32643578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.